These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38851563)

  • 21. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
    Chakrabarty A; Sánchez V; Kuba MG; Rinehart C; Arteaga CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2718-23. PubMed ID: 21368164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
    Garrett JT; Olivares MG; Rinehart C; Granja-Ingram ND; Sánchez V; Chakrabarty A; Dave B; Cook RS; Pao W; McKinely E; Manning HC; Chang J; Arteaga CL
    Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5021-6. PubMed ID: 21385943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
    Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
    Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
    MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.
    Momeny M; Tienhaara M; Sharma M; Chakroborty D; Varjus R; Takala I; Merisaari J; Padzik A; Vogt A; Paatero I; Elenius K; Laajala TD; Kurppa KJ; Westermarck J
    EMBO Mol Med; 2024 Jul; 16(7):1603-1629. PubMed ID: 38886591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
    Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B
    PLoS One; 2017; 12(5):e0177331. PubMed ID: 28493933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pertuzumab: optimizing HER2 blockade.
    Metzger-Filho O; Winer EP; Krop I
    Clin Cancer Res; 2013 Oct; 19(20):5552-6. PubMed ID: 23942091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
    Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
    Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
    Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
    Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.